ENHANCE and ACCORD: controversy over surrogate end points.
Nissen
Steven E
SE
Department of Cardiovascular Medicine, The Cleveland Clinic, 9500 Euclid Avenue, Desk F25, Cleveland, OH 44195, USA. nissens@ccf.org
D000924:Anticholesteremic Agents / Q000627:therapeutic use; D001384:Azetidines / Q000627:therapeutic use; D015415:Biomarkers; D002986:Clinical Trials as Topic; D017327:Clinical Trials, Phase IV as Topic; D023381:Endpoint Determination; D000069438:Ezetimibe; D006442:Glycated Hemoglobin / Q000378:metabolism; D006801:Humans; D006937:Hypercholesterolemia / Q000188:drug therapy; D012107:Research Design; D019821:Simvastatin / Q000627:therapeutic use
D000924:Anticholesteremic Agents; D001384:Azetidines; D015415:Biomarkers; D000069438:Ezetimibe; D006442:Glycated Hemoglobin; D019821:Simvastatin